Hepatitis C, Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Sclerotherapy for the Prevention of Variceal Bleeding in Cirrhosis: A Randomized Multicenter Trial | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search

Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Sclerotherapy for the Prevention of Variceal Bleeding in Cirrhosis: A Randomized Multicenter Trial

table  4.   Encephalopathy
Encephalopathy Sclerotherapy TIPS
Total N° patients (N° episodes) 10 (12)* 21 (39)dagger
First 6 months N° patients (N° episodes) 6 (6) 16 (31)
After 6 months N° patients (N° episodes) 6 (6) 6 (8)
Grade I-II N° episodes 10 31
Grade III-IV N° episodes 3 8
Hospitalized N° patients (N° episodes) 4 (4) 7 (10)
* In this group, two patients underwent TIPS because of rebleeding, and developed 3 episodes of encephalopathy included in the total count. One patient underwent surgical porta-caval anastomosis because of rebleeding and developed an unknown number of episodes of hepatic encephalopathy (only one included in the total count).
In this group, one patient developed chronic recurrent encephalopathy and died after 6 months. Another patient was treated with surgical porta-caval anastomosis because of TIPS failure, and experienced multiple episodes of encephalopathy immediately thereafter (the exact number is unknown, and only one episode is included in the total count). The patient eventually improved and was alive and well at the end of follow-up.


Return To Article

Table Of Contents


Download our Free Reports Download our Free Reports
Thank You!

You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.

If you still haven't received our email after a few minutes, please feel free to contact us.

Close Window